Kaplan-Meier estimates of overall survival of AML intermediate-risk patients in CR1, age 40 to 60 years, by type of postremission therapy (updated results from Cornelissen et al⁵³). HSCT recipients showed significantly better OS than patients receiving chemotherapeutic postremission therapy (P = .001). AlloMAB, myeloablative alloHSCT; AlloRIC, reduced intensity conditioning alloHSCT; Auto, autologous HSCT; CT, chemotherapy; ELN, European Leukemia Net. F, female; LR, logistic regression.